Liver, kidney, and thoracic organ transplantation under FK 506.

PubWeight™: 5.01‹?› | Rank: Top 1%

🔗 View Article (PMC 1358160)

Published in Ann Surg on September 01, 1990


S Todo1, J J Fung, T E Starzl, A Tzakis, A J Demetris, R Kormos, A Jain, M Alessiani, S Takaya, R Shapiro

Author Affiliations

1: Department of Surgery and Pathology, University Health Center of Pittsburgh, University of Pittsburgh, Pennsylvania.

Articles citing this

Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59

The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32

Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31

Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc (1991) 2.26

Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. Transplantation (1993) 2.17

A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09

Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04

The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation (1992) 1.83

The saga of liver replacement, with particular reference to the reciprocal influence of liver and kidney transplantation (1955-1967). J Am Coll Surg (2002) 1.81

Use of FK 506 in pediatric patients. Transplant Proc (1991) 1.77

The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg (1996) 1.71

Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl (2005) 1.61

Immunomodulation for intestinal transplantation by allograft irradiation, adjunct donor bone marrow infusion, or both. Transplantation (2000) 1.53

A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology (1992) 1.50

FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. Surgery (1991) 1.49

Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. Transplantation (1992) 1.45

Clinical intestinal transplantation: a decade of experience at a single center. Ann Surg (2001) 1.44

Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients. Transplant Proc (1991) 1.41

Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J Pediatr (2006) 1.36

Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. Ann Surg (1994) 1.33

Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol (1992) 1.32

Clinical small bowel or small bowel plus liver transplantation under FK 506. Transplant Proc (1991) 1.24

Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. J Clin Pharmacol (1993) 1.23

Tacrolimus in pediatric renal transplantation. Transplantation (1996) 1.18

Adverse effects of FK 506 overdosage after liver transplantation. Transplant Proc (1993) 1.18

Disease gravity and urgency of need as guidelines for liver allocation. Hepatology (1994) 1.16

A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. Transplant Proc (1995) 1.13

Clinical intestinal transplantation: focus on complications. Transplant Proc (1992) 1.11

FK506 in pediatric kidney transplantation--primary and rescue experience. Pediatr Nephrol (1995) 1.11

Current status of FK 506 in liver transplantation. Transplant Proc (1991) 1.04

Expressive dysphasia possibly related to FK506 in two liver transplant recipients. Transplantation (1990) 1.04

What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg (1999) 1.02

Themes of liver transplantation. Hepatology (2010) 0.98

Acquired immunologic tolerance: with particular reference to transplantation. Immunol Res (2007) 0.97

Indocyanine green elimination test in orthotopic liver recipients. Hepatology (1996) 0.96

An appraisal of pediatric liver transplantation from living relatives. Initial clinical experiences in 20 pediatric liver transplantations from living relatives as donors. Ann Surg (1992) 0.94

One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events. Transplant Proc (1995) 0.94

The unfinished legacy of liver transplantation: emphasis on immunology. Hepatology (2006) 0.93

A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation (1994) 0.93

Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl (2001) 0.93

History of clinical transplantation. World J Surg (2000) 0.91

Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506. Transplant Proc (1993) 0.90

Tacrolimus (FK506)-Associated Renal Pathology. Adv Anat Pathol (1997) 0.90

Interaction between FK506 and clotrimazole in a liver transplant recipient. Transplantation (1991) 0.86

The superiority of tacrolimus in renal transplant recipients -- the Pittsburgh experience. Clin Transpl (1995) 0.85

Heart transplantation for dilated cardiomyopathy. Arch Dis Child (1995) 0.84

The relationship of systemic hemodynamics and oxygen consumption to early allograft failure after liver transplantation. Transpl Int (1993) 0.83

The role of the NFAT signaling pathway in retinal neovascularization. Invest Ophthalmol Vis Sci (2013) 0.82

Evaluation of a novel "intelligent" dosing system for optimizing FK 506 therapy. Transplant Proc (1991) 0.81

Effect of FK 506 on spontaneous diabetes in BB rats. Diabetes (1990) 0.81

FK 506 prevents spontaneous diabetes in the BB rat. Transplant Proc (1991) 0.80

New-onset diabetes after transplantation in tacrolimus-treated, living kidney transplantation: long-term impact and utility of the pre-transplant OGTT. Int Urol Nephrol (2010) 0.80

Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK 506). Ann Intern Med (1993) 0.80

Correlation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection. Transplant Proc (1991) 0.79

The mystique of organ transplantation. J Am Coll Surg (2005) 0.78

Renal transplantation at the University of Pittsburgh: the impact of FK506. Clin Transpl (1994) 0.78

Science, specialization, and the American Surgical Association. Ann Surg (1997) 0.78

A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report. Transplantation (2001) 0.78

Intestinal transplantation. Annu Rev Med (1994) 0.78

Acute paranoid psychosis as sole clinical presentation of hepatic artery thrombosis after living donor liver transplantation. BMC Surg (2010) 0.76

Hepatic transplantation at the University of Pittsburgh: new horizons and paradigms after 30 years of experience. Clin Transpl (1994) 0.76

Overview of FK506 in transplantation. Clin Transpl (1990) 0.76

The current status of hepatic transplantation at the University of Pittsburgh. Clin Transpl (1995) 0.76

The mother lode of liver transplantation, with particular reference to our new journal. Liver Transpl Surg (1998) 0.75

The changing face of liver transplantation. Gut (1993) 0.75

Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntlet. Am J Kidney Dis (1998) 0.75

Notes on FK 506. Transplant Proc (1991) 0.75

Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction. J Heart Lung Transplant (1997) 0.75

The development of clinical renal transplantation. Am J Kidney Dis (1990) 0.75

Pediatric liver transplantation from neonatal donors. Transpl Int (1992) 0.75

Anthony Cerami Award in Translational Medicine: A Journey in Science: The Birth of Organ Transplantation with Particular Reference to Alloengraftment Mechanisms. Mol Med (2015) 0.75

Articles cited by this

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

A highly sensitive method to assay FK-506 levels in plasma. Transplant Proc (1987) 8.45

Kidney transplantation under FK 506. JAMA (1990) 7.45

FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) (1987) 7.07

A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature (1989) 7.02

Cyclosporine. N Engl J Med (1989) 5.67

A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature (1989) 5.53

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

Liver transplantation (1). N Engl J Med (1989) 4.53

Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73

Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol (1987) 3.30

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation (1987) 2.40

Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med (1989) 1.94

The refolding of urea-denatured ribonuclease A is catalyzed by peptidyl-prolyl cis-trans isomerase. Biochim Biophys Acta (1985) 1.75

Transplantation. JAMA (1990) 1.71

Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA (1989) 1.40

Liver transplantation: a 31-year perspective. Part I. Curr Probl Surg (1990) 1.20

Posttransplant diabetes in kidney transplant recipients. Am J Nephrol (1985) 1.17

Articles by these authors

Evolution of liver transplantation. Hepatology (1982) 19.54

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24

A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet (1984) 10.33

The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

Orthotopic liver transplantation in ninety-three patients. Surg Gynecol Obstet (1976) 8.11

Kidney transplantation under FK 506. JAMA (1990) 7.45

The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40

The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet (1967) 7.24

Fifteen years of clinical liver transplantation. Gastroenterology (1979) 7.19

Venous bypass in clinical liver transplantation. Ann Surg (1984) 7.04

Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Orthotopic homotransplantation of the human liver. Ann Surg (1968) 6.64

Vascular homografts from cadaveric organ donors. Surg Gynecol Obstet (1979) 6.23

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78

Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) (1988) 5.77

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74

Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70

Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54

Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc (1974) 5.53

Extended survival in 3 cases of orthotopic homotransplantation of the human liver. Surgery (1968) 5.44

Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39

Cyclophosphamide and whole organ transplantation in human beings. Surg Gynecol Obstet (1971) 5.24

Alternative methods of arterialization of the hepatic graft. Surg Gynecol Obstet (1984) 5.16

Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03

Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

Liver transplantation (1). N Engl J Med (1989) 4.53

Pancreaticoduodenal transplantation in humans. Surg Gynecol Obstet (1984) 4.49

Nucleic acid reactivity and conformation. II. Reaction of cytosine and uracil with sodium bisulfite. J Biol Chem (1973) 4.44

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29

Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29

Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16

Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12

Malignant lymphomas in transplantation patients. Transplant Proc (1969) 4.12

Role of liver transplantation in cancer therapy. Ann Surg (1985) 4.08

Biliary complications after liver transplantation: with special reference to the biliary cast syndrome and techniques of secondary duct repair. Surgery (1977) 4.08

Shwartzman reaction after human renal homotransplantation. N Engl J Med (1968) 4.05

Baboon-to-human liver transplantation. Lancet (1993) 4.01

Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med (2001) 4.01

Extended preservation of human liver grafts with UW solution. JAMA (1989) 3.99

Canine and human liver preservation for 6 to 18 hr by cold infusion. Transplantation (1977) 3.99

Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92

Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation (1985) 3.91

X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet (2001) 3.86

The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions. Surg Gynecol Obstet (1967) 3.86

Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85

The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med (2001) 3.85

The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet (1973) 3.84

Massive outbreak of Escherichia coli O157:H7 infection in schoolchildren in Sakai City, Japan, associated with consumption of white radish sprouts. Am J Epidemiol (1999) 3.75

Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs. Lancet (1976) 3.74

Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73

Hepatic trisegmentectomy and other liver resections. Surg Gynecol Obstet (1975) 3.66

Right trisegmentectomy for hepatic neoplasms. Surg Gynecol Obstet (1980) 3.64

Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

Hepatic Retransplantation. Transplant Proc (1985) 3.62

Transplantation of multiple abdominal viscera. JAMA (1989) 3.59

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55

Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54

Implementation of a high-sensitivity Micro-Angiographic Fluoroscope (HS-MAF) for in-vivo endovascular image guided interventions (EIGI) and region-of-interest computed tomography (ROI-CT). Proc SPIE Int Soc Opt Eng (2008) 3.49

Combination donor hepatectomy and nephrectomy and early functional results of allografts. Surg Gynecol Obstet (1982) 3.49

Long-term survival after renal transplantation in humans: (with special reference to histocompatibility matching, thymectomy, homograft glomerulonephritis, heterologous ALG , AND RECIPIENT MALIGNANCY). Ann Surg (1970) 3.48

Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43

The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant (2011) 3.42

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet (1981) 3.38

The relation of preoperative coagulation findings to diagnosis, blood usage, and survival in adult liver transplantation. Transplantation (1985) 3.38

Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34